...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Reply from Sarah

I still think we're in for a big dilution on our Newco shares. Here's what I (still) see based on the uber limited info available....

1. Prior to the split there are about 103 million Zenith Epigenetics (ZEC) shares valued at $1.00 US. Total valuation = $103 million.

2. As the company has stated, "34.4 million Class A common shares of Newco at a deemed price of US$1.00 per share." Total valuation for Newco = $34.4 million.

3. Therefore, Newco's valuation is ~1/3 of the original ZEC.

4. Therefore, if, prior to the split, you had 300 shares of ZEC (@ $1), you would now have 100 shares of Newco (@ $1).

You can't now have 300 shares of Newco (@ $1). That would be 100% of your pre-split holdings.




Share
New Message
Please login to post a reply